| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2023 | 828.68% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/24/2023 | 828.68% | HC Wainwright & Co. | → $5 | Initiates Coverage On | → Buy |
| 05/26/2023 | 1200.15% | Stifel | $1.3 → $7 | Upgrades | Hold → Buy |
| 05/10/2023 | 921.55% | Credit Suisse | $7 → $5.5 | Maintains | Outperform |
| 03/09/2023 | 1200.15% | Credit Suisse | $8 → $7 | Maintains | Outperform |
| 01/09/2023 | 85.74% | JMP Securities | $2 → $1 | Maintains | Market Outperform |
| 01/06/2023 | 1385.88% | Credit Suisse | $10 → $8 | Maintains | Outperform |
| 11/17/2022 | 271.47% | JMP Securities | $5 → $2 | Maintains | Market Outperform |
| 08/11/2022 | 828.68% | JMP Securities | $8 → $5 | Maintains | Market Outperform |
| 03/17/2022 | 2500.3% | Credit Suisse | $16 → $14 | Maintains | Outperform |
| 01/25/2022 | 2871.77% | Credit Suisse | $20 → $16 | Maintains | Outperform |
| 01/25/2022 | 1051.56% | Stifel | $20 → $6.2 | Downgrades | Buy → Hold |
| 01/25/2022 | 1385.88% | JMP Securities | $33 → $8 | Maintains | Market Outperform |
| 11/09/2021 | 3614.71% | Stifel | → $20 | Upgrades | Hold → Buy |
| 10/12/2021 | 3614.71% | Credit Suisse | → $20 | Initiates Coverage On | → Outperform |
| 10/04/2021 | 3614.71% | Mizuho | → $20 | Initiates Coverage On | → Buy |
| 09/21/2021 | 6029.27% | JMP Securities | → $33 | Initiates Coverage On | → Market Outperform |
| 09/20/2021 | 3614.71% | Stifel | → $20 | Initiates Coverage On | → Hold |
| 09/13/2021 | 9186.78% | Cantor Fitzgerald | → $50 | Initiates Coverage On | → Overweight |
What is the target price for eFFECTOR Therapeutics (EFTR)?
The latest price target for eFFECTOR Therapeutics (NASDAQ: EFTR) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $5.00 expecting EFTR to rise to within 12 months (a possible 828.68% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for eFFECTOR Therapeutics (EFTR)?
The latest analyst rating for eFFECTOR Therapeutics (NASDAQ: EFTR) was provided by HC Wainwright & Co., and eFFECTOR Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for eFFECTOR Therapeutics (EFTR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of eFFECTOR Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for eFFECTOR Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
Is the Analyst Rating eFFECTOR Therapeutics (EFTR) correct?
While ratings are subjective and will change, the latest eFFECTOR Therapeutics (EFTR) rating was a reiterated with a price target of $0.00 to $5.00. The current price eFFECTOR Therapeutics (EFTR) is trading at is $0.54, which is within the analyst's predicted range.